Søren Møller
#138,605
Most Influential Person Now
Researcher
Søren Møller's AcademicInfluence.com Rankings
Søren Møllercomputer-science Degrees
Computer Science
#6515
World Rank
#6868
Historical Rank
Computational Linguistics
#1140
World Rank
#1154
Historical Rank
Machine Learning
#2139
World Rank
#2167
Historical Rank
Artificial Intelligence
#2400
World Rank
#2441
Historical Rank
Download Badge
Computer Science
Søren Møller's Degrees
- PhD Computer Science Aarhus University
- Masters Computer Science Aarhus University
- Bachelors Computer Science Aarhus University
Similar Degrees You Can Earn
Why Is Søren Møller Influential?
(Suggest an Edit or Addition)Søren Møller's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. (2010) (1548)
- Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease (2002) (338)
- Cardiovascular complications of cirrhosis (2008) (324)
- Interactions of the heart and the liver. (2013) (319)
- Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites (2009) (297)
- Serum YKL-40 is increased in patients with hepatic fibrosis. (2000) (261)
- Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease (2003) (219)
- Cirrhotic cardiomyopathy: pathogenesis and clinical relevance (2014) (193)
- Systematic review with meta‐analysis: the effects of rifaximin in hepatic encephalopathy (2014) (166)
- An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. (1995) (141)
- The sympathetic nervous system in liver disease. (1998) (135)
- Cardiovascular complications of cirrhosis. (2009) (128)
- Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients. (2000) (128)
- Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis (2012) (124)
- Acute non-selective beta-adrenergic blockade reduces prolonged frequency-adjusted Q-T interval (QTc) in patients with cirrhosis. (2004) (124)
- Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis. (1995) (123)
- Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome (2007) (119)
- Plasma YKL-40: a new potential marker of fibrosis in patients with alcoholic cirrhosis? (1997) (117)
- Lactate metabolism in chronic liver disease (2013) (111)
- Dyssynchronous electrical and mechanical systole in patients with cirrhosis. (2002) (109)
- Endothelin‐1 and ‐3 plasma concentrations in patients with cirrhosis: Role of splanchnic and renal passage and liver function (1995) (106)
- Increased circulating leptin in alcoholic cirrhosis: Relation to release and disposal (1999) (105)
- Endothelin-1 and endothelin-3 in cirrhosis: relations to systemic and splanchnic haemodynamics. (1995) (105)
- The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis (2018) (104)
- GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion. (2002) (102)
- Determinants of the hyperdynamic circulation and central hypovolaemia in cirrhosis (2011) (95)
- New insights into cirrhotic cardiomyopathy. (2013) (95)
- Insulin‐like growth factor‐I and the liver (2011) (93)
- BNP and N‐terminal proBNP are both extracted in the normal kidney (2006) (90)
- Prognostic variables in patients with cirrhosis and oesophageal varices without prior bleeding. (1994) (88)
- Decreased right heart blood volume determined by magnetic resonance imaging: Evidence of central underfilling in cirrhosis (1995) (86)
- Concentrations, release, and disposal of insulin-like growth factor (IGF)-binding proteins (IGFBP), IGF-I, and growth hormone in different vascular beds in patients with cirrhosis. (1995) (86)
- The acid-labile subunit of human ternary insulin-like growth factor binding protein complex in serum: hepatosplanchnic release, diurnal variation, circulating concentrations in healthy subjects, and diagnostic use in patients with growth hormone deficiency. (1998) (86)
- Noninvasive 24‐hour ambulatory arterial blood pressure monitoring in cirrhosis (1995) (86)
- Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension (2013) (83)
- Cirrhotic cardiomyopathy. (2010) (82)
- Elevated circulating plasma endothelin-1 concentrations in cirrhosis. (1993) (77)
- Cardiovascular dysfunction in cirrhosis. Pathophysiological evidence of a cirrhotic cardiomyopathy. (2001) (76)
- Blood volume distribution in patients with cirrhosis: aspects of the dual-head gamma-camera technique. (2001) (76)
- Current limits and future challenges in the management of renal dysfunction in patients with cirrhosis: report from the International Club of Ascites (2013) (74)
- Reduced baroreflex sensitivity in alcoholic cirrhosis: relations to hemodynamics and humoral systems. (2007) (72)
- Plasma volume expansion by albumin in cirrhosis. Relation to blood volume distribution, arterial compliance and severity of disease. (2003) (70)
- Cardiac and proinflammatory markers predict prognosis in cirrhosis (2014) (69)
- Effect of 1,25-dihydroxy-vitamin D3 in experimental sepsis (2007) (68)
- Cardiopulmonary complications in chronic liver disease. (2006) (68)
- Arterial hypoxaemia in cirrhosis: fact or fiction? (1998) (67)
- Effects of a single terlipressin administration on cardiac function and perfusion in cirrhosis (2010) (66)
- The Systemic Circulation in Cirrhosis (2007) (65)
- Extrahepatic complications to cirrhosis and portal hypertension: haemodynamic and homeostatic aspects. (2014) (65)
- Arterial compliance in patients with cirrhosis: stroke volume-pulse pressure ratio as simplified index. (2001) (64)
- A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy (2012) (62)
- Effect of octreotide on systemic, central, and splanchnic haemodynamics in cirrhosis. (1997) (61)
- Prolonged Q-T(c) interval in mild portal hypertensive cirrhosis. (2005) (59)
- WITHDRAWN: Kowalski HJ, Abelmann WH. The cardiac output in Laennec's cirrhosis [J Clin Invest 1953;32:1025-1033] (2003) (59)
- Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double‐blind, placebo‐controlled trial (2017) (58)
- Central and noncentral blood volumes in cirrhosis: relationship to anthropometrics and gender. (2003) (57)
- Circulatory abnormalities in cirrhosis with focus on neurohumoral aspects. (1997) (55)
- Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome (2008) (54)
- The cardiorenal link in advanced cirrhosis. (2012) (53)
- Splanchnic and systemic hemodynamic derangement in decompensated cirrhosis. (2001) (52)
- Cardiac and systemic haemodynamic complications of liver cirrhosis (2009) (52)
- Flutamide-induced liver failure. (1990) (52)
- Effects of terlipressin on the aquaretic system: evidence of antidiuretic effects. (2008) (51)
- Diurnal variation and dispersion in QT interval in cirrhosis: relation to haemodynamic changes. (2007) (51)
- Prognostic value of insulinlike growth factor I and its binding protein in patients with alcohol‐induced liver disease (1996) (50)
- Vasoactive substances in the circulatory dysfunction of cirrhosis (2001) (50)
- Liver cirrhosis and arterial hypertension. (2006) (49)
- Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial (2018) (49)
- Increased arterial compliance in decompensated cirrhosis. (1999) (48)
- EXERCISE IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA – A RANDOMIZED, CONTROLLED TRIAL OF EFFECTS ON PHYSICAL FUNCTION, PHYSICAL ACTIVITY, PAIN AND QUALITY OF LIFE (2020) (48)
- Cardiac dysfunction in cirrhosis – does adrenal function play a role? A hypothesis (2012) (47)
- Insulin-like growth factor 1 (IGF-1) in burn patients. (1991) (47)
- The heart and the liver (2009) (47)
- Kidney injury in cirrhosis: pathophysiological and therapeutic aspects of hepatorenal syndromes (2014) (46)
- Pathogenesis and pathophysiology of hepatorenal syndrome – is there scope for prevention? (2004) (46)
- Pathogenetic background for treatment of ascites and hepatorenal syndrome (2008) (45)
- Autonomic dysfunction in cirrhosis and portal hypertension (2008) (45)
- Carvedilol or propranolol in portal hypertension? A randomized comparison (2012) (44)
- Insulin-like growth factor 1 and growth hormone in chronic liver disease. (1992) (44)
- Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation (2020) (43)
- Urinary growth hormone (U-GH) excretion and serum insulin-like growth factor 1 (IGF-1) in patients with alcoholic cirrhosis. (1993) (42)
- Review article: volume expansion in patients with cirrhosis (2002) (42)
- High-sensitivity C-reactive protein levels predict survival and are related to haemodynamics in alcoholic cirrhosis (2012) (42)
- Meal-induced changes in splanchnic blood flow and oxygen uptake in middle-aged healthy humans (2006) (39)
- Increased renal production of C-type natriuretic peptide (CNP) in patients with cirrhosis and functional renal failure (2000) (39)
- High arterial compliance in cirrhosis is related to low adrenaline and elevated circulating calcitonin gene related peptide but not to activated vasoconstrictor systems (2001) (39)
- Cirrhotic Multiorgan Syndrome (2015) (39)
- Ascites: Pathogenesis and therapeutic principles (2009) (39)
- Effect of terlipressin on blood volume distribution in patients with cirrhosis (2004) (39)
- Arterial hypertension in cirrhosis: arterial compliance, volume distribution, and central haemodynamics (2006) (39)
- Carbohydrate deficient transferrin (CDT) in alcoholic cirrhosis: a kinetic study. (1997) (39)
- Bile acids and cardiovascular function in cirrhosis (2017) (38)
- Pro-C5, a marker of true type V collagen formation and fibrillation, correlates with portal hypertension in patients with alcoholic cirrhosis (2015) (37)
- Management of cirrhotic ascites (2015) (37)
- Cardiodynamic state is associated with systemic inflammation and fatal acute‐on‐chronic liver failure (2020) (37)
- Pulmonary dysfunction and hepatopulmonary syndrome in cirrhosis and portal hypertension (2009) (36)
- Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis (2018) (36)
- Effect of oxygen inhalation on systemic, central, and splanchnic haemodynamics in cirrhosis. (1996) (35)
- Cirrhotic cardiomyopathy. (2018) (34)
- Short-term effect of recombinant human growth hormone in patients with alcoholic cirrhosis. (1994) (34)
- Beta-blockers in cirrhosis and refractory ascites: a retrospective cohort study and review of the literature (2015) (33)
- Optimized analysis of recurrent bleeding and death in patients with cirrhosis and esophageal varices. Copenhagen Esophageal Varices Sclerotherapy Project. (1994) (33)
- Effects of tilting on central hemodynamics and homeostatic mechanisms in cirrhosis (2004) (33)
- Soluble TNF-Alpha-Receptors I Are Prognostic Markers in TIPS-Treated Patients with Cirrhosis and Portal Hypertension (2013) (33)
- The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis (2016) (32)
- The soluble mannose receptor (sMR) is elevated in alcoholic liver disease and associated with disease severity, portal hypertension, and mortality in cirrhosis patients (2017) (32)
- Determinants of the renin-angiotensin-aldosterone system in cirrhosis with special emphasis on the central blood volume (2006) (32)
- Relation of calcitonin gene-related peptide to systemic vasodilatation and central hypovolaemia in cirrhosis. (1996) (32)
- Elevated circulating leptin levels in arterial hypertension: relationship to arteriovenous overflow and extraction of leptin. (2000) (31)
- Transjugular intrahepatic portosystemic shunt: impact on systemic hemodynamics and renal and cardiac function in patients with cirrhosis. (2018) (31)
- PRO-C3-Levels in Patients with HIV/HCV-Co-Infection Reflect Fibrosis Stage and Degree of Portal Hypertension (2014) (30)
- Cardiac and renal effects of a transjugular intrahepatic portosystemic shunt in cirrhosis (2013) (30)
- Treatment of acute variceal bleeding. (2008) (30)
- Endothelins in chronic liver disease. (1996) (29)
- Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET). (2019) (28)
- Pathophysiological basis of pharmacotherapy in the hepatorenal syndrome (2005) (28)
- New vasoactive peptides in cirrhosis: organ extraction and relation to the vasodilatory state (2014) (27)
- Pathophysiological aspects of pulmonary complications of cirrhosis (2007) (26)
- Prognostic value of 18F-FET PET imaging in re-irradiation of high-grade glioma: Results of a phase I clinical trial. (2016) (26)
- Alterations of Hepatic and Splanchnic Microvascular Exchange in Cirrhosis: Local Factors in the Formation of Ascites (2007) (26)
- Diastolic and autonomic dysfunction in early cirrhosis: a dobutamine stress study (2014) (26)
- An update on cirrhotic cardiomyopathy (2019) (25)
- Pancreatic function and morphology in Sjögren's syndrome (2010) (25)
- Q‐T interval (QTC) in patients with cirrhosis: relation to vasoactive peptides and heart rate (2007) (25)
- Assessment of response to beta-blockers by expression of βArr2 and RhoA/ROCK2 in antrum mucosa in cirrhotic patients. (2016) (25)
- Indocyanine green retention test (ICG-r15) as a noninvasive predictor of portal hypertension in patients with different severity of cirrhosis (2016) (25)
- Continuous blood pressure monitoring in cirrhosis. Relations to splanchnic and systemic haemodynamics. (1997) (24)
- TIMP-1 in patients with cirrhosis: relation to liver dysfunction, portal hypertension, and hemodynamic changes (2014) (24)
- Diastolic dysfunction in cirrhosis (2016) (24)
- Clinical Characteristics of Gliosarcoma and Outcomes From Standardized Treatment Relative to Conventional Glioblastoma (2019) (23)
- Myocardial extracellular volume quantified by magnetic resonance is increased in cirrhosis and related to poor outcome (2018) (23)
- Indications for portal pressure measurement in chronic liver disease (2012) (23)
- Serum Neutrophil Gelatinase-Associated Lipocalin – A Sensitive Novel Marker of Renal Impairment in Liver Cirrhosis? (2011) (22)
- Combined antiretroviral therapy attenuates hepatic extracellular matrix remodeling in HIV patients assessed by novel protein fingerprint markers (2014) (22)
- Effects of transjugular intrahepatic portosystemic shunt (TIPS) on blood volume distribution in patients with cirrhosis. (2017) (22)
- Betablockers induce cardiac chronotropic incompetence. (2012) (22)
- Hyponatraemia during terlipressin therapy (2010) (21)
- Neurohumoral fluid regulation in chronic liver disease. (1998) (21)
- Complications of cirrhosis. A 50 years flashback (2015) (21)
- Cardiac imaging in patients with chronic liver disease (2017) (20)
- Association of markers of bacterial translocation with immune activation in decompensated cirrhosis (2014) (20)
- Toxicity and efficacy of re-irradiation of high-grade glioma in a phase I dose- and volume escalation trial. (2017) (20)
- Cardiac sympathetic imaging with mIBG in cirrhosis and portal hypertension: relation to autonomic and cardiac function. (2012) (19)
- The acid-labile subunit of the ternary insulin-like growth factor complex in cirrhosis: relation to liver dysfunction. (2000) (19)
- Indocyanine green retention test in cirrhosis and portal hypertension: Accuracy and relation to severity of disease (2018) (19)
- No difference in portal and hepatic venous bacterial DNA in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt insertion (2013) (19)
- Effects of carvedilol and propranolol on circulatory regulation and oxygenation in cirrhosis: a randomised study. (2014) (19)
- Collagen type IV remodelling gender‐specifically predicts mortality in decompensated cirrhosis (2019) (18)
- Systemic haemodynamics in cirrhosis and portal hypertension with focus on vasoactive substances and prognosis. (1998) (18)
- Cardiac output determined by echocardiography in patients with cirrhosis: comparison with the indicator dilution technique (2003) (18)
- Acid–base disturbance in patients with cirrhosis: relation to hemodynamic dysfunction (2015) (17)
- Endoscopic Doppler ultrasound for measurement of azygos blood flow. Validation against thermodilution and assessment of pharmacological effects of terlipressin in portal hypertension. (2001) (17)
- Hepatic and renal extraction of circulating type I procollagen aminopropeptide in patients with normal liver function and in patients with alcoholic cirrhosis. (1999) (17)
- Increased circulating calcitonin in cirrhosis. Relation to severity of disease and calcitonin gene-related peptide. (2000) (16)
- Cardiac Function in Patients with Early Cirrhosis during Maximal Beta-Adrenergic Drive: A Dobutamine Stress Study (2014) (16)
- Non‐invasive measurement of cardiac output by Finometer in patients with cirrhosis (2010) (16)
- Haemodynamics and fluid retention in liver disease. (1998) (15)
- Progressive alcohol‐related liver fibrosis is characterised by imbalanced collagen formation and degradation (2021) (15)
- Does cardiac dysfunction explain deleterious effects of beta‐blockers in cirrhosis and refractory ascites? (2011) (15)
- Hepatorenal syndrome in cirrhosis: diagnostic, pathophysiological, and therapeutic aspects (2016) (15)
- Circulating Elastin Fragments Are Not Affected by Hepatic, Renal and Hemodynamic Changes, But Reflect Survival in Cirrhosis with TIPS (2015) (14)
- Who benefits from endoscopic sclerotherapy of bleeding oesophageal varices? Proposal for differential indications. The Copenhagen Esophageal Varices Sclerotherapy Project. (1992) (14)
- Cardiac dysfunction in cirrhosis: a 2-year longitudinal follow-up study using advanced cardiac imaging. (2019) (14)
- Impaired free water excretion in child C cirrhosis and ascites: relations to distal tubular function and the vasopressin system (2010) (13)
- Adherence to guidelines in bleeding oesophageal varices and effects on outcome: comparison between a specialized unit and a community hospital (2010) (13)
- Increased prognostic value of combined myocardial perfusion imaging and exercise electrocardiography in patients with coronary artery disease (2000) (12)
- Effect of beta-adrenergic blockade on elevated arterial compliance and low systemic vascular resistance in cirrhosis. (2001) (12)
- Fibrogenesis and inflammation contribute to the pathogenesis of cirrhotic cardiomyopathy (2020) (11)
- Increased Arterial Compliance in Cirrhosis is Related to Decreased Arterial C-type Natriuretic Peptide, but not to Atrial Natriuretic Peptide (2003) (11)
- Elevated carboxy terminal cross linked telopeptide of type I collagen in alcoholic cirrhosis: relation to liver and kidney function and bone metabolism (1999) (11)
- Validation of non‐invasive haemodynamic methods in patients with liver disease: the Finometer and the Task Force Monitor (2018) (11)
- Cardiorenal Syndrome - A New Entity ? (2011) (11)
- Amiodarone for rapid cardioversion of chronic atrial tachyarrhythmia? (2000) (11)
- Expression of vasoactive proteins in gastric antral mucosa reflects vascular dysfunction in patients with cirrhosis and portal hypertension (2015) (11)
- The soluble mannose receptor is released from the liver in cirrhotic patients, but is not associated with bacterial translocation (2017) (11)
- Pulmonary blood volume and transit time in cirrhosis: relation to lung function. (2006) (10)
- A comparison of circulating and regional growth hormone-binding protein in cirrhosis. (2001) (10)
- Hypertension and liver disease (2004) (10)
- Reduced baroreflex sensitivity and pulmonary dysfunction in alcoholic cirrhosis: effect of hyperoxia. (2010) (9)
- Detection of early central circulatory transits in patients with cirrhosis by gamma variate fit of indicator dilution profiles. (2005) (9)
- Hyponatremia in patients treated with terlipressin: Mechanisms and implications for clinical practice (2011) (9)
- Effect of 1,25-dihydroxy-vitamin D 3 in experimental sepsis (2007) (9)
- Total bile acid levels are associated with left atrial volume and cardiac output in patients with cirrhosis (2017) (9)
- Prognosis in patients with cirrhosis and mild portal hypertension (2006) (8)
- Treatment of ascites and spontaneous bacterial peritonitis - part I. (2012) (8)
- Arm lean mass determined by Dual-energy X-ray absorptiometry is superior to characterize skeletal muscle and predict sarcopenia-related mortality in cirrhosis. (2021) (8)
- Pronounced Coronary Arteriosclerosis in Cirrhosis: Influence on Cardiac Function and Survival? (2018) (8)
- Immunologic, hemodynamic, and adrenal incompetence in cirrhosis: impact on renal dysfunction (2014) (8)
- Grohth hormone (GH) excretion and serum insulin-like growth factor-1 (IGF-1) in cirrhosis (1991) (8)
- Elevated Arterial Compliance in Patients with Cirrhosis Is Not Related to Arterial Endothelin-1 (2002) (8)
- Circulating nitric oxide products do not solely reflect nitric oxide release in cirrhosis and portal hypertension (2011) (7)
- Predictive value of indocyanine green retention test and indocyanine green clearance in Child‐Pugh class A patients (2015) (7)
- Normal red cell cardiac output in the hyperkinetic syndrome of alcoholic cirrhosis. (2001) (7)
- Early changes in perfusion of glioblastoma during radio- and chemotherapy evaluated by T1-dynamic contrast enhanced magnetic resonance imaging (2015) (7)
- Pulmonary blood volume and transit time in cirrhosis: relation to lung function (2006) (7)
- Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease (2022) (7)
- 755 CARDIAC FUNCTION STUDIED BY DOBUTAMIN STRESS MRI IN PATIENTS WITH MILD CIRRHOSIS (2009) (7)
- Effects of a single dose of terlipressin on transcutaneous oxygen pressures (2010) (6)
- Effects of Transjugular Intrahepatic Portosystemic Shunt (Tips) on Blood Volume Distribution in Patients with Cirrhosis (2016) (6)
- Assessment of systolic function in the evaluation of patients with cirrhosis (2017) (6)
- Left atrial volume changes assessed by real time 3-dimensional echocardiography in relation to liver function and prognosis in patients with cirrhosis (2020) (6)
- Plasma ADAMTS-13 protein is not associated with portal hypertension or hemodynamic changes in patients with cirrhosis. (2016) (6)
- 99mTc‐labelled human serum albumin cannot replace 125I‐labelled human serum albumin to determine plasma volume in patients with liver disease (2013) (6)
- Assessment of central blook volume in cirrhosis by radionusclide angiography: What does it really mean? (1994) (6)
- Extracranial metastases in glioblastoma—Two case stories (2018) (6)
- [234] CARDIAC EFFECTS OF TERLIPRESSIN IN CIRRHOSI S. UNMASKING A CIRRHOTIC CARDIOMYOPATHY? (2007) (6)
- No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial (2018) (6)
- Hepatic erythropoietin response in cirrhosis (2016) (6)
- Colonic lactulose fermentation has no impact on glucagon-like peptide-1 and peptide-YY secretion in healthy young men. (2021) (5)
- Outcome of splanchnic blood flow determination in patients with suspected chronic intestinal ischaemia. A retrospective survey (2002) (5)
- The royal free hospital cirrhosis glomerular filtration rate: Validation in a danish cohort (2017) (5)
- Rifaximin for people with hepatic encephalopathy (2015) (5)
- Using MR elastography to assess portal hypertension and response to beta‐blockers in patients with cirrhosis (2021) (5)
- Dobutamine reverses the cardio-suppressive effects of terlipressin without improving renal function in cirrhosis and ascites: a randomised controlled trial. (2019) (5)
- Effects of the vasopressin agonist terlipressin on plasma cAMP and ENaC excretion in the urine in patients with cirrhosis and water retention (2011) (5)
- The insulin like growth factor system in cirrhosis. Relation to changes in body composition following adrenoreceptor blockade. (2012) (5)
- Volume expansion in patients with cirrhosis (2002) (5)
- Neutrophil gelatinase‐associated lipocalin and cystatin C in cirrhosis and portal hypertension: Relations to organ extraction and dysfunction (2017) (5)
- Vagal mediation of systemic cardiovascular response to portal hypertension: from experimental studies in animals to treatment of humans (2008) (5)
- A Prognostic Model for Glioblastoma Patients Treated With Standard Therapy Based on a Prospective Cohort of Consecutive Non-Selected Patients From a Single Institution (2021) (5)
- Tunneled Peritoneal Catheter for Refractory Ascites in Cirrhosis: A Randomized Case-Series (2020) (4)
- Safety of Terlipressin for Hepatorenal Syndrome (2011) (4)
- Pathophysiological-based treatments of complications of cirrhosis (2020) (4)
- Cardiac Biomarkers in Cirrhosis and Portal Hypertension: Relation to Circulatory and Cardiac Dysfunction (2015) (4)
- Effect of recombinant human growth hormone (rHGH) on insulin-like growth factor 1 (IGF-1) in patients with cirrhosis of the liver (1991) (4)
- [Cirrhotic cardiomyopathy: prolonged QTc-interval and dyssynchronic electrical and mechanical systole in cirrhosis]. (2004) (4)
- Cardiovascular Mapping in Cirrhosis From the Compensated Stage to Hepatorenal Syndrome: A Magnetic Resonance Study (2022) (4)
- Novel Anti-inflammatory Treatments in Cirrhosis. A Literature-Based Study (2021) (4)
- Advances in the treatment of portal hypertension in cirrhosis (2016) (3)
- Cardiovascular complications in liver diseasesKowalski HJ, Abelmann WH. The cardiac output in Laennec's cirrhosis. [J Clin Invest 1953;32:1025–1033] (2003) (3)
- Patients with cirrhosis have elevated bone turnover but normal hepatic production of osteoprotegerin. (2021) (3)
- [Portal hypertensive gastropathy]. (1995) (3)
- Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms (2021) (3)
- Aquaporin‐2 excretion in hospitalized patients with cirrhosis: Relation to development of renal insufficiency and mortality (2017) (3)
- [Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome]. (1993) (3)
- 295 LOW CARDIAC INDEX PREDICTS SURVIVAL AND RENAL FAILURE IN PATIENTS WITH ASCITES. EVIDENCE OF A HEART-KIDNEY AXIS IN CIRRHOSIS (2008) (3)
- NAFLD: Cardiovascular complications of NAFLD—they do matter (2015) (3)
- Mechanisms in fluid retention – towards a mutual concept (2019) (3)
- Divergences in Macrophage Activation Markers Soluble CD163 and Mannose Receptor in Patients With Non-cirrhotic and Cirrhotic Portal Hypertension (2021) (3)
- [Severe toxic hepatitis during flutamide (Eulexin) treatment]. (1989) (3)
- Effects of treatment with &bgr;-blocker and aldosterone antagonist on central and peripheral haemodynamics and oxygenation in cirrhosis (2011) (3)
- Assessment of central blood volume in cirrhosis by radionuclide angiography (1994) (3)
- Energy expenditure and loss of muscle and fat mass in patients with walled-off pancreatic necrosis: A prospective study. (2019) (3)
- Assessment of portal hypertension severity using machine learning models in patients with compensated cirrhosis. (2022) (3)
- The Psychometric Hepatic Encephalopathy Syndrome score does not correlate with blood ammonia, endotoxins or markers of inflammation in patients with cirrhosis. (2021) (3)
- Kinetics of the soluble urokinase plasminogen activator receptor (suPAR) in cirrhosis (2019) (3)
- Dipeptidyl peptidase-3 is associated with severity of liver disease and circulatory complications in patients with cirrhosis (2021) (2)
- [Hepatorenal syndrome: diagnosis, treatment and prevention]. (2013) (2)
- Arterial hypertension and chronic liver disease. (2005) (2)
- Pharmacological effects are model specific in animal models of portal hypertension (2008) (2)
- [Prognostic value of insulin-like growth factor I-IGF-I--and its binding protein IGFBP-3 in alcoholic liver disease]. (1997) (2)
- Assessment of diastolic function in the management of patients with cirrhosis (2014) (2)
- [Prediction of bleeding risks and death in cirrhosis based on hemodynamic and metabolic variables. A study of patients with esophageal varices without previous bleeding]. (1995) (2)
- Variceal Rebleeding: Drugs, Endoscopy or Both (2014) (2)
- Hepatic erythropoietin response in cirrhosis. A contemporary review (2016) (2)
- Toward new standards for noninvasive measuring of portal pressure? (2015) (2)
- [The blood pressure lowering effect of chlorpromazine and methylperon (Buronil)]. (1974) (1)
- Association of low mechano‐energetic efficiency and prognosis in liver cirrhosis (2022) (1)
- Editorial: measuring inflammatory and fibrotic components of portal hypertension – a non‐invasive hepatic venous pressure gradient? Authors’ reply (2016) (1)
- Prolonged QT-interval in cirrhosis: is it reversible? (2020) (1)
- Treatment of the hepatorenal syndrome and hyponatremia in cirrhosis - part II. (2012) (1)
- Minimally invasive assessment of hepatic function in children with indocyanine green elimination: a validation study (2019) (1)
- The heart and other organs Interactions of the heart and the liver (2013) (1)
- Transjugular intrahepatic portosystemic shunt: impact on systemic haemodynamics and renal and cardiac function in patients with cirrhosis (2017) (1)
- RT-22MRI AND FET PET FOR RADIOTHERAPY PLANNING IN RECURRENT HIGH-GRADE GLIOMA (HGG) IN A PROSPECTIVE PHASE I TRIAL (2014) (1)
- Cardiac fibrosis and coronary atherosclerosis in cirrhosis. Indications of cirrhotic cardiomyopathy (2018) (1)
- P1337 : Randomized trial with rifaximin in liver cirrhosis. Effects on the haemodynamic and inflammatory state (2015) (1)
- Pathophysiology Behind Cardiopulmonary Complications of Cirrhosis and Portal Hypertension (2020) (1)
- Pituitary adenylate cyclase‐activating peptide: Potential roles in the pathophysiology and complications of cirrhosis (2020) (1)
- [Determination of diurnal blood pressure variations in cirrhosis]. (1996) (1)
- 527 IMBALANCES IN PROINFLAMMATORY CYTOKINES ARE ASSOCIATED WITH PULMONARY DYSFUNCTION AND HEPATOPULMONARY SYNDROME IN CIRRHOSIS (2010) (1)
- Determination of hepatic clearance by derivations of the indocyanine green retention test in cirrhosis (2022) (1)
- The Effect of Liver Disease on the Cardiovascular System (2008) (1)
- Normal gastrointestinal protein loss in portal hypertensive gastropathy. (1994) (1)
- [Portal hypertensive gastropathy in cirrhosis]. (1993) (1)
- 169 CARVEDILOL OR PROPRANOLOL IN PORTAL HYPERTENSION? A RANDOMIZED CLINICAL TRIAL (2010) (1)
- [The hepatorenal syndrome. From physiopathology to clinical practice]. (2004) (1)
- Cardiovascular reactions to myelography with watersoluble contrast media (1977) (1)
- [The hepatorenal syndrome]. (1995) (1)
- [Intravenous urography with diatrizoate, iothalamate and metrizoate]. (1972) (1)
- Enhanced processing of von Willebrand factor reflects disease severity and discriminates severe portal hypertension in cirrhosis (2019) (1)
- The role of bile acids in the development of structural myocardial changes and cardiac dysfunction in patients with cirrhosis (2018) (1)
- Early identification of patients with bleeding oesophageal varices treatable by sclerotherapy (1989) (1)
- [Should renal vein catheterization for selective renin determination be performed in patients with suspected renovascular hypertension?]. (2004) (1)
- [Myocardial scintigraphy. Clinical use and consequence in a non-invasive cardiological department]. (2006) (1)
- [Treatment of bleeding from oesophageal varices in patients with cirrhosis]. (2007) (1)
- [Segmental "portal hypertension". A rare cause of severe tractable variceal bleeding]. (1997) (0)
- Haemodynamic and humoral effects of posture in patients with cirrhosis and controls (2003) (0)
- Socioeconomic status and risk of osteoporotic fractures or use of DXA-scanning: data from the Danish population-based ROSE study (2017) (0)
- P939 NGAL IN PATIENTS WITH LIVER CIRRHOSIS: RELATION TO PATIENT CHARACTERISTICS AND KINETICS (2014) (0)
- Distribution of blood volumes in cirrhosis. Relation to gender and antropometrics (2003) (0)
- Hepatorenalt syndrom: diagnose, behandling og forebyggelse: diagnosis, treatment and prevention (2013) (0)
- Cardiovascular Effects of a Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis (2017) (0)
- Inverse relationship between the media-to-lumen ratio and smooth muscle contractile function in resistance arteries from patients with residual cardiovascular disease (2018) (0)
- PO-0655: Stereotactic RT of recurrent high-grade glioma based on FET-PET and MRI: Initial results of a dose escalation trial (2013) (0)
- 514 CIRCULATING SCD163, A SCAVENGER RECEPTOR RELEASED FROM ACTIVATED MACROPHAGES, IS ASSOCIATED WITH PORTAL HYPERTENSION IN PATIENTS WITH LIVER CIRRHOSIS (2010) (0)
- S1962 Effects of Terlipressin On the Aquaretic System - Evidence of Antidiuretic Effects (2008) (0)
- 585 CARDIAC ADRENERGIC FUNCTION ASSESSED BY I-METAIODOBENZYL/GUANIDINE MYOCARDIAL SCINTIGRAPHY IN PATIENTS WITH CIRRHOSIS (2012) (0)
- 252 EFFECTS OF TERLIPRESSIN ON THE AQUARETIC SYSTEM. EVIDENCE OF ANTIDIURETIC EFFECTS (2008) (0)
- Systemic haemodynamic complications of liver cirrhosis (2008) (0)
- Does local sympathetic atrophy contribute to splanchnic vasodilation in portal hypertension? (2010) (0)
- 610 PROGNOSTIC POTENTIAL OF CARDIAC AND PROINFLAMMATORY MARKERS IN CIRRHOSIS (2013) (0)
- Peripheral plasma C-peptide levels do not accuratly reflext prehepatic insulin secretion after intravenous glucose (2008) (0)
- Effectiveness of a two-step population based osteoporosis screening programme using FRAX (Risk-stratified Osteoporosis Strategy Evaluation (ROSE)): A randomised prospective population based study (2017) (0)
- Different inflammasome activation predisposes for acute-on-chronic liver failure depending on hepatic compensation in human and experimental liver cirrhosis (2020) (0)
- Validation of an obstetric comorbidity index: a nationwide cohort study (2019) (0)
- Possible Relevance of Soluble Luteinizing Hormone Receptor during Development and Adulthood in Boys and Men (2021) (0)
- [Blood pressure determination]. (2002) (0)
- FRI-130-Changes in the extracellular matrix of the heart and the liver assessed by MRI with T1-mapping are closely linked in cirrhosis: Is inflammation the shared pathway? (2019) (0)
- Arterial compliance in cirrhosis. Relation to pathophysiology andeffect of vasoconstriction (2000) (0)
- An unusual case of chylous ascites: A case report (2014) (0)
- The association between self-rated health, self-perceived fracture risk and fracture risk among women screened for osteoporosis - The Rose study (2018) (0)
- SAT-027-Effects of propranolol on liver- and spleen-stiffness measured by MR-Elastography in patients with cirrhosis (2019) (0)
- 225 THE PROTEIN FINGERPRINT TECHNOLOGY REFLECTS LIVER FUNCTION AND DETECTS CLINICALLY SIGNIFICANT PORTAL HYPERTENSION IN PATIENTS WITH ALCOHOLIC LIVER CIRRHOSIS (2013) (0)
- Cirrhotic cardiomyopathy: Toward an optimized definition (2022) (0)
- The PHES Score Does Not Correlate With Blood Ammonia Levels, Circulating Endotoxins or Markers of Systemic Inflammation (2017) (0)
- pegylated interferon plus ribavirin in patients with chronic hepatitis C: A prospective randomized pilot study (2012) (0)
- 294 CRITICAL ISCHAEMIA IN PERIPHERAL LIMBS DURING TERLIPRESSIN TREATMENT (2008) (0)
- Aquaporin-2 in Cirrhosis: Relation to Disease Severity, Markers of Renal Function and Impact on Development of Renal Insufficiency and Mortality (2016) (0)
- 572 CARDIAC FUNCTION AND DYNAMICS OF QT INTERVAL IN PATIENTS WITH MILD CIRRHOSIS DURING MAXIMAL BETA-ADRENERGIC DRIVE: A DOBUTAMIN STRESS STUDY (2012) (0)
- Long term survival of patients with Evans syndrome: A population-based cohort study (2018) (0)
- Systemic inflammation is associated with cardiodynamic state in acute-on-chronic liver failure (2020) (0)
- 206 RIFAXIMIN IN THE TREATMENT AND PROPHYLAXIS OF HEPATIC ENCEPHALOPATHY IN CHRONIC LIVER DISEASE: A META-ANALYSIS (2013) (0)
- Blunted cardiovascular effects of beta-blockers in patients with cirrhosis: Relation to severity? (2022) (0)
- 733 NEOEPITOPES DERIVED FROM EXTRACELLULAR MATRIX DEGRADATION REFLECT LIVER FUNCTION, FIBROSIS AND HVPG IN HIV-PATIENTS (2013) (0)
- 90 EVIDENCE OF A VASOPRESSIN-INDEPENDENT AQP2 EXPRESSION AND WATER RETENTION IN REFRACTORY ASCITES (2008) (0)
- Practice Guidelines EASL clinical practice guidelines on the management of ascites , spontaneous bacterial peritonitis , and hepatorenal syndrome in cirrhosis European Association for the Study of the Liver 1 (2010) (0)
- Long-time effects of a slow release somatostatin analogue (Lanreotide SR) on hepatic venous pressure gradient in patients with proven esophageal varices (2003) (0)
- Different injection techniques in the assessment of central haemodynamics in patients with cirrhosis (2013) (0)
- [238] PULMONARY FUNCTION IN CIRRHOSIS: LOW PREVALENCE OF THE HEPATOPULMONARY SYNDROME (2007) (0)
- The composition of the bile acid pool is closely associated with fibrosis in the heart and liver of patients with cirrhosis (2022) (0)
- 636 EFFECTS OF ALPHA- AND BETA-ADRENERGIC BLOCKADE ON CIRCULATORY REGULATION AND OXYGENATION IN CIRRHOSIS (2012) (0)
- Peptidylglycine alpha-amidating monooxygenase and adrenomedullin measurements suggest cardio-circulatory dysfunction in advanced cirrhosis (2022) (0)
- 308 Occupational risk factors for hip and knee osteoarthritis – evidence of gene-exposure interaction: a co-twin control study in danish twins (2018) (0)
- Increased levels of soluble mannose receptor are associated with poor outcome in cirrhosis: results from a 2-year longitudinal study (2020) (0)
- Demographic , clinical , and biochemical characteristics of 22 patients with cirrhosis and ascites (2008) (0)
- Research update for articles published in EJCI in 2014 (2016) (0)
- [Heart-circulation-dysfunction in liver disease: cirrhotic cardiomyopathy?]. (2004) (0)
- 247 HIGH LEVELS OF SOLUBLE TNF-ALPHA-RECEPTOR-I ARE ASSOCIATED WITH POOR OUTCOME IN CIRRHOSIS WITH PORTAL HYPERTENSION (2013) (0)
- High prevalence of Shiga toxin-producing Escherichia coli harbouring only Shiga toxin 1 in Danish patients referred to gastroenterology clinics (2018) (0)
- Altered serum bile acid composition is associated with cardiac dysfunction in cirrhosis. (2023) (0)
- 591 BACTERIAL DNA MEASUREMENTS IN PATIENTS WITH CIRRHOSIS UNDERGOING TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) INSERTION (2013) (0)
- 584 NEW VASCULAR BIOMARKERS IN CIRRHOSIS: ORGAN EXTRACTION AND RELATION TO THE VASODILATORY STATE (2013) (0)
- S1961 Critical Ischaemia in Peripheral Limbs During Terlipressin Treatment (2008) (0)
- FRI-120-Structural liver disease rather than portal hypertension is the predominant factor for hepatic macrophage activation in patients with cirrhosis, portal vein thrombosis and idiopathic portal hypertension (2019) (0)
- [Malrotation of the duodenum and duodenal ulcer]. (1976) (0)
- P940 IS CYSTATIN C (CYSTC) AN IDEAL MARKER OF RENAL DYSFUNCTION IN CIRRHOSIS (2014) (0)
- The Transition From Conformal Photon Radiation Therapy to Arc Therapy for High-Grade Gliomas (2012) (0)
- PD-0247 IMPACT OF TRANSITION FROM 3D-CONFORMAL TO VOLUMETRIC MODULATED ARC THERAPY FOR HIGH-GRADE GLIOMAS (2012) (0)
- [25th anniversary of the Danish Society of Physiology and Nuclear Medicine]. (2007) (0)
- 710 TIMP-1 IN PATIENTS WITH CIRRHOSIS: RELATION TO LIVER DYSFUNCTION, PORTAL HYPERTENSION, AND HAEMODYNAMIC CHANGES (2013) (0)
- [Cirrhotic cardiomyopathy: increased circulating pro-brain natriuretic peptide and brain natriuretic peptide in cirrhosis]. (2004) (0)
- Octreotide in cirrhotic patients (1998) (0)
- Peptidylglycine α-Amidating Monooxygenase And Adrenomedullin Measurement In Cirrhosis Suggesting Cardiomyopathy (2021) (0)
- [Does the administration of dipyridamole affect the ventilatory capacity of patients with chronic obstructive lung disease?]. (2005) (0)
- function portal hypertension : relation to autonomic and cardiac IBG in cirrhosis and m Cardiac sympathetic imaging with (2014) (0)
- Half of patients with multiple myeloma with rehabilitation needs report moderate to severe symptoms or functional problems (2019) (0)
- Reply to Cailes et al. (2023) (0)
- [A complicated course of Salmonella gastroenteritis during antihypertensive treatment]. (2000) (0)
- Cardiac and pulmonary complications in portal hypertension (2008) (0)
- Cardiopulmonary complications in chronic liver disease hypertension; (2014) (0)
- 176 EFFECTS OF TREATMENT WITH BETA-BLOCKER AND ALDOSTERONE ANTAGONIST ON CENTRAL AND PERIPHERAL HAEMODYNAMICS AND OXYGENATION IN CIRRHOSIS (2011) (0)
- P516 Pro-C5: A NOVEL SEROLOGICAL MARKER OF TRUE TYPE V COLLAGEN FORMATION DETECTS PORTAL HYPERTENSION IN CIRRHOSIS (2014) (0)
- The effect of terlipressin on blood volume distribution in patients with cirrhosis (2002) (0)
- Validation and robustness of the Fracture Risk Evaluation Model (FREM): A register-based cohort study (2019) (0)
- Hemodynamic and humoral effects of posture in patients with cirrhosis and in controls (2003) (0)
- Patients with alcoholic-related cirrhosis have high burden of coronary arteriosclerosis compared to non-alcohol-related cirrhosis (2017) (0)
- Pitfalls in the assessment of intrapulmonary shunt using lung perfusion scintigraphy in patients with cirrhosis: authors' reply (2011) (0)
- Strategier til forbedring af patient-reported outcome data komplethed (2019) (0)
- [Cirrhotic cardiomyopathy--true or false?]. (1998) (0)
- Statins for cirrhosis: almost ready for clinical application (2020) (0)
- Tunnelated peritoneal catheter versus large volume paracentesis for refractory ascites in cirrhosis: a randomized controlled trial (2020) (0)
- [The diagnostic value of splanchnic blood flow determination in patients with suspected chronic intestinal ischemia]. (2004) (0)
- Machine learning models for prediction of severe portal hypertension in patients with compensated cirrhosis (2022) (0)
- [Cyanide poisoning]. (2003) (0)
- [Portal pressure should be measured on suspicion of portal hypertension]. (2010) (0)
- Growth hormone binding protein in cirrhosis: normal or decreased? (2002) (0)
- Postprandial dysfunction in fatty liver disease (2023) (0)
- RARE-21. CLINICAL CHARACTERISTICS OF GLIOSARCOMA AND OUTCOME FROM STANDARDIZED TREATMENT RELATIVE TO CONVENTIONAL GLIOBLASTOMA (2019) (0)
- 188 Reduced baroreceptor reflex sensitivity in cirrhosis. Relations to central haemodynamics and humoral systems (2006) (0)
- [Is it still possible to become a hepatologist? The Danish Society of Hepatology]. (2004) (0)
- 801 - Liver Cirrhosis and Wound Healing: Activation of Von Willebrand Factor and Platelets (2018) (0)
- Evidence of a vasopressin-independent AQP2 expression and water retention in patients with Child C cirrhosis and ascites (2008) (0)
- Liver cirrhosis and wound healing: Activation of von Willebrand factor and platelets (2018) (0)
- Long-term changes of pancreatic function in patients with complicated walled-off necrosis (2022) (0)
- Indications and methods for measuring portal hypertension in cirrhosis (2022) (0)
- [Alcohol-related liver cirrhosis and related complications]. (2021) (0)
- A Persistent Worldwide Environmental Hazard: Former Manufactured Gas Plant (fmgp) Sites Association of an Fmgp Site with Childhood Neuroblastoma (2008) (0)
- [Autonomic dysfunction in chronic liver disease]. (1997) (0)
- SAT-055-Dobutamine counteracts the decrease in cardiac output after terlipressin in patients with cirrhosis and impaired kidney function but does not improve GFR: A randomised exploratory trial (2019) (0)
- Renal and circulatory effects of terlipressin in patients with hepatorenal syndrome assessed by magnetic resonance imaging (2022) (0)
- Assessment by 24-Hour Blood Pressure Monitoring in Cirrhosis (2006) (0)
- 584 ASSOCIATIONS BETWEEN BAROREFLEX SENSITIVITY, CARDIOVASCULAR REGULATION AND CENTRAL HYPOVOLAEMIA IN CIRRHOSIS AND PORTAL HYPERTENSION (2012) (0)
- Long term survival of patients with Evans syndrome: A population-based cohort study. European Haematology (2018) (0)
- [Susceptibility of uropathogenic bacteria to mecillinam, ampicillin and a combination of mecillinam and ampicillin]. (1985) (0)
- MRI-derived myocardial extracellular volume is closely associated with markers of collagen formation in cirrhosis (2020) (0)
- SAT-138-Cirrhotic cardiomyopathy: A 2-year longitudinal follow-up study using advanced cardiac imaging (2019) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Søren Møller?
Søren Møller is affiliated with the following schools:
